Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growth

What happened

Last week, 23 healthcare companies reported results. Of those, 22 beat earnings-per-share estimates, 16 posted year-over-year earnings growth, and all 23 posted year-over-year revenue growth. AbbVie, Eli Lilly, and Bristol Myers Squibb were named as reporters.

Confirmed

Global impact / market context

Broad revenue growth and frequent estimate beats suggest demand for treatments stayed strong, supporting company revenue and cash available to reinvest. Stronger profit per sale can fund research and capital spending, while raised guidance signals management expects continued growth.

Analyst inference

Investors often read wide estimate beats as a sign that healthcare earnings expectations were too low. Because all named reporters grew revenue, sector-focused funds tracking healthcare and biotechnology may attract interest tied to expectations of steady medicine demand.

Analyst inference

What to watch

1. AbbVie raised its FY2026 adjusted EPS guidance to $13.95–$13.99 from $13.76–$13.96, which means management expects higher profit per share. Confirmed
2. Eli Lilly raised its FY2026 revenue outlook to $91B–$92B while reporting Q3 revenue of $24.40B, up 39% from a year earlier. Confirmed
3. Watch whether other healthcare reporters that beat estimates also raise full-year guidance, since that would show whether the stronger outlook is broad rather than limited to a few firms. Proposed

Evidence

• seekingalpha.com